Daxor Corporation Announces New Research Initiative with Leading Hospital in the Southeast and the...

NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...

DAXOR CORPORATION ANNOUNCES NEW PARTNERSHIP WITH LEADING HOSPITAL IN NORTH CAROLINA TO INTEGRATE THE...

Tailwinds' Take: this is very positive for Daxor. If momentum starts to accelerate, DXR could be a great stock. We'd like to know if...

Daxor Shares Reverse…If You Missed It Before, Here’s Your Chance

From the December lows of around $6, Daxor shares shot up more than 300% to a recent high of $20 in early March. The...

Daxor Corporation to Showcase Reduction in Mortality and Hospital Readmissions with BVA-100® Guided-Care at...

NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...

CEO Interview: Michael Feldschuh of Daxor Corp. (DXR)

Tailwinds Research - First off, let’s get into the data. You recently announced positive results at an industry conference. Can you speak about the...

Daxor Corporation Announces Rise in Kit Sales and Files Form N-CSR For 2018

Tailwinds' Take: we eventually expect to see a sharp uptick in growth from this already strong rate as the implications of the pivotal trial...

Daxor Investor Letter

Daxor Corporation  February 28, 2019 Dear Fellow Shareholder: Daxor Corporation (“Daxor”or the “Company”) is an investment company with medical instrumentation and biotechnology operations. We have attached a...

New Research Further Demonstrates Clinical Utility and Improved Ease of Use with Daxor Corporation’s...

Tailwinds' Take: "Less blood draws, quicker results". This research further positions the BVA-100 as a must have for hospitals. The big catalyst here? We...

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 48th Congress

Tailwinds' Take: Looking forward to seeing more data on the BVA-100. The medical community is just waking up to the incredible savings in mortality...

Daxor Emerges

Accurate blood volume monitoring can save lives and reduce medical costs The BVA 100 is the only approved product on the market Hospitals...

Daxor Corporation Appoints Guido Manzo, Vice President of Sales

NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement...

Daxor Corporation Announces Acquisition of BVA-100® Blood Volume Analyzer to Aspirus Wausau Hospital in...

NEW YORK, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood...

New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) in Evaluation...

NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.